"There is a growing need for research into mental health conditions like TR-PTSD and TR-OCD, and psychedelic-assisted psychotherapy shows significant promise for treating both of these conditions," said Dr.
There is little effective therapy for chronic PTSD and despite decades of research, therapeutic options at the chronic stage are mostly limited to rehabilitation and symptom relief, resulting in substantial unmet need for a solution. Preliminary research into psychedelic-assisted psychotherapy for OCD has demonstrated a decrease in symptoms, pointing to the necessity for controlled proof of concept trials to further substantiate its safety and efficacy for TR-OCD.
"The successful export of PEX010 to
The clinical trial at
Learn more at www.filament.health and on Twitter, Instagram, and LinkedIn.
Certain statements and information contained herein may constitute "forward‐looking statements" and "forward‐looking information," respectively, under Canadian securities legislation. Generally, forward‐looking information can be identified by the use of forward‐looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward‐looking statements or information. The forward‐looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward‐looking statements. Forward‐looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward‐looking statements or forward‐looking information, including status of patent applications and the ability to secure patents. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐ looking statements and forward‐looking information. Filament will not update any forward‐ looking statements or forward‐looking information that are incorporated by reference herein, except as required by applicable securities laws.
SOURCE
© Canada Newswire, source